Novo, FDA and Ozempic

Shortage of Novo's Wegovy and Ozempic is resolved, FDA website shows
A shortage of Danish drugmaker Novo Nordisk's popular weight-loss and diabetes drugs, Wegovy and Ozempic, has been resolved, the U.S. Food and Drug Administration's website showed on Friday.
Novo’s Ozempic, Wegovy Shortage Ends, Threatening Copycats
Novo Nordisk A/S’s weight-loss and diabetes drugs are no longer in short supply, US regulators said, a decision that’s expected to curtail widespread access to cheaper copies of the popular medications.
US FDA says shortage of Novo's weight-loss drug resolved
The resolution comes two months after the health regulator said there was no longer a shortage of Eli Lilly's weight-loss and diabetes drugs. All doses of Novo's diabetes treatment Ozempic and weight-loss drug Wegovy were listed as available on the FDA's website in October,
Novo Nordisk up 6%, Hims & Hers down 15% as FDA says Ozempic shortage over
Shares of Novo Nordisk (NVO) are up 6% in pre-market trading after a FDA drug shortage notice indicated that a shortage of several versions of
U.S. attorneys general forum urges FDA to act against counterfeit weight loss drugs
A bipartisan group of U.S. state and territory attorneys general is pressing the FDA to take prompt action against those threatening public health by marketing counterfeit forms of branded weight loss medications developed by Novo Nordisk (NVO) and Eli Lilly (NYSE:LLY).
Novo Nordisk A/S (NVO): Is It The Most Oversold Healthcare Stock to Buy Now?
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
Does Medicare Cover Ozempic?
Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...
Is Novo Nordisk's Bottom Here? Oversold Status Below 10Y P/E Lows
Novo Nordisk faces challenges but its pipeline remains strong. Find out why NVO stock could deliver high double-digit returns ...
STAT18h
Dozens of attorneys general urge FDA to crack down on counterfeit obesity drugs
More than three dozen attorneys general are urging the FDA to take “decisive action” against counterfeit obesity drugs.
Novo Nordisk alleges fraud after $1.3 billion deal to buy hypertension drug from KBP Biosciences
Novo Nordisk is seeking up to $830 million in damages from KBP Biosciences, according to a ruling by a Singapore court, as ...
Why Novo Nordisk Is A Strong Buy Despite Market Concerns
Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...